Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY – Research Report), Neurocrine (NBIX – Research Report) and Globus Medical (GMED – Research Report).
Alnylam Pharma (ALNY)
In a report released today, Kostas Biliouris from BMO Capital maintained a Buy rating on Alnylam Pharma, with a price target of $234.00. The company’s shares closed last Tuesday at $198.20.
According to TipRanks.com, Biliouris is a 3-star analyst with an average return of
Alnylam Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $229.41, representing a 16.6% upside. In a report issued on January 2, Bernstein also maintained a Buy rating on the stock with a $220.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Neurocrine (NBIX)
BMO Capital analyst Evan Seigerman maintained a Hold rating on Neurocrine yesterday and set a price target of $116.00. The company’s shares closed last Tuesday at $133.71, close to its 52-week high of $134.93.
According to TipRanks.com, Seigerman is a 4-star analyst with an average return of
Currently, the analyst consensus on Neurocrine is a Moderate Buy with an average price target of $136.17, a 1.6% upside from current levels. In a report issued on January 3, RBC Capital also maintained a Hold rating on the stock with a $129.00 price target.
Globus Medical (GMED)
Barclays analyst Matt Miksic reiterated a Buy rating on Globus Medical yesterday and set a price target of $83.00. The company’s shares closed last Tuesday at $53.84.
According to TipRanks.com, Miksic is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Globus Medical with a $64.91 average price target, implying a 21.8% upside from current levels. In a report issued on December 28, Stifel Nicolaus also maintained a Buy rating on the stock with a $61.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALNY:
- Alnylam price target raised to $237 from $233 at Citi
- Alnylam reports preliminary Q4, FY23 global net product revenues
- The Smid-cap biotech stocks to own in 2024, according to Bernstein
- Alnylam price target raised to $220 from $216 at Bernstein
- William Blair sees ATTR-PN market as large enough for two players
